Close Menu

NEW YORK (GenomeWeb) – MDxHealth reported today that its first quarter revenues rose 50 percent, thanks to a 55 percent increase in total test volumes.

For the three months ended March 31, the molecular diagnostics company said revenues rose to $9.7 million from $6.5 million in Q1 2017. Included in the total revenue for Q1 was a license fee payment of $500,000. Product revenues from the firm's ConfirmMDx and SelectMDx tests for prostate cancer amounted to $7.9 million and rose 60 percent from $4.9 million a year earlier.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.

China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.

In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.

NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.